Skip to content

Platelet Rich Fibrin and Concentrated Growth Factors on Osseointegration of Immediate Implants

A Comparative Study Between the Effect of Platelet-rich Fibrin and Concentrated Growth Factors on Osseointegration of Immediate Implants (a Randomized Clinical Trial)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05101954
Enrollment
14
Registered
2021-11-01
Start date
2020-10-01
Completion date
2021-08-17
Last updated
2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tooth Extraction, Dental Implants

Brief summary

This study will involve 14 patients with mandibular premolars indicated for extraction and immediate replacement. The patients will be randomly allocated into two groups and each patient will receive one implant. In Group A, a CGF membrane will be laid in the implant cavity. While in Group B, a PRF membrane will be laid in the implant cavity. Bone graft material will be applied to fill the empty parts of the socket. Resonance frequency measurement will be done using the OSTELL device intraoperatively, at the 1st week and after 3 months. Cone-beam computed tomography will be done preoperatively, immediately following surgery, and after 3 months

Interventions

Concentrated Growth Factors membrane will be laid in the implant cavity. Bone graft material will be applied to fill the empty parts of the socket.

Platelet-Rich Fibrin (PRF) membrane will be laid in the implant cavity. Bone graft material will be applied to fill the empty parts of the socket.

Sponsors

Hams Hamed Abdelrahman
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Cooperative patients with good oral hygiene. * Patients having a history of mandibular premolars indicated for extraction and immediate replacement.

Exclusion criteria

* Heavy smokers. * Parafunctional occlusal habits. * Uncontrolled diabetes. * History of chemotherapy or radiotherapy. * Hematological disorders that prevent either implantation or centrifugation. * Pregnancy. * The nee¬d for additional augmentation or previous augmentation of the same region. * Chronic periapical pathology

Design outcomes

Primary

MeasureTime frameDescription
Change in implant stabilityimmediately, at 1 week, at 3 monthsOsstell instrument (Integration Diagnostics, Goteborg, Sweden) with Smartpeg™ (Integration Diagnostics, Goteborg, Sweden), a transducer suitable for implants will be used to assess stability of implants by RFA. ISQ (implant stability quotient) will be obtained from the measurement results. During measurement, the Smartpeg™ will be placed over the location of implant prosthesis and the Osstell probe will be approximated to it from the buccal, palatal, mesial and distal aspects of the implant giving four ISQ values. A mean ISQ for each implant is then calculated by averaging the four values. The ISQ values of the implants will be measured during the operation, at the first week and three months after the operation.
Change in Bone densityimmediately, after 3 monthsThe Patients will be asked to do CBCT immediately after surgery and after 3 months
Change in bone formationimmediately, after 3 monthsAmount of bone formed buccal and lingual to the implant will be assessed using CBCT
Marginal bone lossafter 3 monthsit will be assessed using CBCT

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026